CapEx at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s capex?
- Krystal Biotech, Inc. (KRYS) reported capex of $7.15M in Q1 2026.
- How has Krystal Biotech, Inc.'s capex changed year-over-year?
- Krystal Biotech, Inc.'s capex increased by 15.2% year-over-year, from $6.2M to $7.15M.
- What is the long-term trend for Krystal Biotech, Inc.'s capex?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s capex has grown at a -35.3% compound annual growth rate (CAGR), from $68.34M to $11.95M.
- What does capex mean?
- Cash spent on buying or upgrading long-term physical assets.
- How do you interpret capex?
- High expenditures signal investment in future production capacity, whereas low expenditures may indicate a focus on asset-light operations.
- How does capex compare across companies?
- Standard for biotech companies building out manufacturing capabilities for gene therapies.